CHGCF - Chugai Pharmaceutical Co. Ltd. (CHGCF) Q1 2024 Earnings Call Transcript

2024-04-24 23:40:02 ET

Chugai Pharmaceutical Co., Ltd. (CHGCF)

Q1 2024 Earnings Conference Call

April 24, 2024 5:00 AM ET

Company Participants

Kae Miyata - Head of Corporate Communications

Osamu Okuda - President and Chief Executive Officer

Tsukasa Kusano - Executive Vice President, Head of Project & Lifecycle Management Unit

Iwaaki Taniguchi - Chief Financial Officer

Junichi Takano - Head of Marketing and Sales

Conference Call Participants

Shinichiro Muraoka - Morgan Stanley

Seiji Wakao - JPMorgan Securities Japan Co., Ltd.

Hidemaru Yamaguchi - Citigroup Inc.

Kazuaki Hashiguchi - Daiwa Securities Group Inc.

Miki Sogi - AllianceBernstein Japan

Akinori Ueda - Goldman Sachs Japan Co., Ltd.

Presentation

Kae Miyata

My name is Miyata. I will be facilitating today’s session. And this session is held using a Zoom webinar platform. As Page 3 of the presentation material speaks, we would like to go through today’s preceding as per agenda.

Today’s presentations are made in Japanese. However, we do have English simultaneous interpretation service available. Please make sure you select the luggage of your preference by clicking on the bookmark on your screen. For those who wish to listen to Japanese, please select Japanese. For those who wish to listen in English, please select English. And please make sure that you click on mute original audio. This way you can only listen to the language of your choice. We will take questions after the presentation. We plan to spend about 30 minutes for Q&A session. During the presentation session, you are all muted.

Now, I would like to invite Okuda to give us the review of the first quarter result of 2024.

Osamu Okuda

My name is Okuda speaking. I am the Representative and CEO. I would like to explain about the result of the first quarter of 2024. Please refer to the Slide #5. The first quarter made a strong start for the core business as being expected. Revenue dropped by 24.1% in one year. This was because last year in the same period, we have had a supply of Ronapreve to the government of ¥81.2 billion....

For further details see: